ocular hypertension and primary open-angle glaucoma
Ophthalmology · 2012–2012
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tafluprost Treatment of ocular hypertension and primary open-angle glaucoma, as monotherapy or as adjunctive therapy to beta blockers. | Mar 2012 | Recommended with restriction | no section in document |
| tafluprost Treatment of ocular hypertension and primary open-angle glaucoma, as monotherapy or as adjunctive therapy to beta blockers. | Mar 2012 | Recommended with restriction | no section in document |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| latanoprost netarsudilLatanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | recommended restricted | 2024-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.